Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) EPS (Weighted Average and Diluted) (2022 - 2025)

Lucid Diagnostics (LUCD) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.1 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 60.0% year-over-year to -$0.1, compared with a TTM value of -$0.79 through Sep 2025, up 30.09%, and an annual FY2024 reading of -$1.05, up 16.67% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.1 for Q3 2025 at Lucid Diagnostics, down from -$0.08 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.08 in Q2 2025 and bottomed at -$0.52 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.3, with a median of -$0.31 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 65.35% in 2025, while the deepest fall reached 30.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.4 in 2022, then soared by 37.5% to -$0.25 in 2023, then soared by 32.0% to -$0.17 in 2024, then surged by 41.18% to -$0.1 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for LUCD at -$0.1 in Q3 2025, -$0.08 in Q2 2025, and -$0.52 in Q1 2025.